On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.
Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.
The INLIGHT interim readout reported a 14.3% placebo-adjusted reduction in visceral fat six months after a single dose, alongside preservation of lean muscle mass - a differentiated profile compared to GLP-1 therapies that often reduce muscle alongside fat.
We are continuing to execute our prediction markets treasury strategy, and we are pleased that Lind provided us with substantial capital, stated Shai Novik, Executive Chairman of Enlivex.
RBC Capital analyst Luca Issi upgraded the stock to Outperform from Sector Perform with a price target of $35, up from $11. Wells Fargo also upgraded uniQure to Overweight from Equal Weight with a $60 price target. The catalyst: the departure of Vinay Prasad from the FDA. RBC views this as a positive for uniQure, noting it is "not inconceivable" that the FDA reverts to its prior stance, and believes Prasad's departure is likely to open up a more balanced discussion on risk/reward for Huntington's disease.
X4 Pharmaceuticals drew a fresh initiation from Guggenheim, which assigned a Buy rating and $12 price target, framing the company as a "differentiated hematology play" with significant upside in the next 18 months. The firm's thesis centers on mavorixafor, a potential first-in-class oral CXCR4 antagonist already approved for WHIM syndrome and currently in Phase 3 development for primary chronic neutropenia.
For families living with neurodegenerative disease, the hardest part is not always the diagnosis. It is the slow erosion that follows: memory fading, personality shifting, independence shrinking. It unfolds quietly. First, forgotten appointments. Then repeated questions. Then moments when a familiar face no longer feels familiar. The illness does not isolate itself to one body. It rearranges the lives around it.
Lund-based MedVasc has announced they have successfully completed production and testing activities in accordance with its plan. In parallel, the company closed a new financing round at the end of 2025, raising € 2.2 million (SEK 24 million) from existing shareholders. With the financing secured, MedVasc is well positioned to accelerate the remaining key activities required for FDA clearance of Solutio™ for the U.S. market. Preparations are progressing according to plan, and market approval is expected during autumn 2026.
Eduardo Vilar-Sanchez has spent more than 10 years pursuing a goal that seemed very distant, but which he now sees as a little closer: to develop a preventive vaccine against cancer. The physician and researcher is leading a study that presented the first promising results of a colon cancer vaccine in a small group of patients suffering from a rare disease that makes them 17 times more likely to develop colon cancer than the general population.
The Wegovy pill-which has been in clinical trials for over two years and was approved by the FDA on December 22-is the first and only oral GLP-1 for weight loss in adults available in the U.S. According to a press release from Novo Nordisk, the pill hit the market on January 5 at more than 70,000 U.S. pharmacies and several popular telehealth providers. Per a KFF health tracking poll released in November, one in eight Americans were already taking a GLP-1 for weight-loss.
We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.
Obesity shaped Anna Olson's earliest notions of herself, when she saw a photo and thought, "Oh, I look different than the other kids." Olson's obesity began in toddlerhood, ran in her family, and left her with a chronic hunger hard to satiate. Dozens of diet, drug and exercise regimens didn't work, and advice from doctors was always the same: Eat less.
